IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation Read more about Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment Read more about Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study Read more about Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights Read more about Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference Read more about Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights Read more about Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights Piper Sandler & Co. Christopher J. Raymond Piper Sandler & Co. Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors Read more about Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology Read more about Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights Read more about Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights Pagination First page « First Previous page ‹ Previous … Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Page 19 Page 20 Page 21 … Next page Next › Last page Last » Subscribe to FAQs Email Alerts Connect
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation Read more about Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment Read more about Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study Read more about Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights Read more about Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference Read more about Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights Read more about Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors Read more about Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology Read more about Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights Read more about Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights